Teva Pharmaceuticals

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a global pharmaceutical company headquartered in Israel. As the world's largest generic drug manufacturer, Teva develops, produces, and markets a wide range of generic and specialty medicines. The company was founded in 1901 and has grown to offer over 3,500 products across more than 60 countries. Teva's portfolio includes treatments for central nervous system disorders, respiratory conditions, and oncology. The company generates approximately one-fifth of its revenue from branded medications, with the remainder coming from its extensive generic drug offerings.

Teva's main products and services include:

• Generic prescription drugs: A wide range of affordable generic medications across multiple therapeutic areas.

• Specialty branded medicines: Patented therapies targeting specific conditions, including:

• Austedo and Ajovy for central nervous system disorders

• Copaxone for multiple sclerosis

• Bendeka and Treanda for cancer treatment

• ProAir and Qvar for respiratory conditions

• Biosimilars: Through partnerships, Teva is expanding its presence in the growing biosimilars market.

• Active Pharmaceutical Ingredients (APIs): Production of raw materials used in drug manufacturing.

In July 2023, Teva expanded its strategic partnership with Alvotech to develop and commercialize additional biosimilar candidates in the US. The company is actively working on expanding its biosimilars pipeline, including pending approvals for Humira and Stelara biosimilars. Teva reported revenue of USD 15.9 billion in 2021. The company's largest market is North America, followed by Europe. Teva has implemented a portfolio rationalization strategy to mitigate price erosion in its generic drug business. The company's 2022 financial outlook projected revenues between USD 15.6 billion and USD 16.2 billion.